Bausch + Lomb has introduced its preloaded enVista Envy intraocular lenses (IOLs) to the European market, adding a premium option to its existing enVista platform and expanding the company’s full‑range vision portfolio.
The enVista Envy lenses feature a preloaded design that simplifies the surgical process, allowing surgeons to implant the lenses with minimal handling and reducing operative time. The lenses also deliver enhanced dysphotopsia tolerance, a key benefit for patients who experience visual disturbances such as glare or halos after cataract surgery.
The European IOL market is projected to reach USD 3 billion by 2031, growing at a CAGR of 6.69%. Bausch + Lomb competes with major players such as Alcon, Johnson & Johnson, and Carl Zeiss Meditec. By adding the enVista Envy line, the company strengthens its position in the premium segment and is better positioned to capture market share in a highly competitive environment.
Bausch Health reported Q4 2025 consolidated revenues of $2.80 billion, up 9% year‑over‑year, and full‑year 2025 revenues of $10.27 billion, up 7% from 2024. The Bausch + Lomb segment generated $1.41 billion in Q4 2025, a 10% increase, underscoring the eye‑health business’s contribution to the group’s top line. The new product launch is expected to support further revenue growth and aligns with the company’s strategy to spin off its eye‑health division.
Luc Bonnefoy, president of Surgical at Bausch + Lomb, said, "Bausch + Lomb now offers two full range of vision premium IOLs – enVista Envy and LuxLife™ to meet the evolving needs of surgeons and patients in Europe." Dr. Sheraz Daya, medical director at Centre for Sight in London, added, "The lens performs extremely well in our experience and does so with minimal photic issues, if any."
The launch supports Bausch + Lomb’s broader goal of strengthening its eye‑health business as a potential spin‑off from Bausch Health. It also follows the company’s response to a voluntary recall of certain enVista IOLs in April 2025, which was resolved after identifying the cause of the reported Toxic Anterior Segment Syndrome cases. By expanding its premium portfolio, Bausch + Lomb aims to capture a larger share of the growing demand for premium cataract surgery solutions in Europe and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.